USA - NASDAQ:APYX - US03837C1062 - Common Stock
ChartMill assigns a Buy % Consensus number of 78% to APYX. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-10-17 | BTIG | Initiate | Neutral |
| 2024-09-16 | JMP Securities | Reiterate | Market Perform |
| 2023-11-10 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2023-08-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-07-14 | Stephens & Co. | Initiate | Overweight |
| 2023-06-15 | Lake Street | Maintains | Buy |
| 2023-05-24 | JMP Securities | Reiterate | Market Perform -> Market Perform |
| 2023-05-12 | Lake Street | Maintains | Buy -> Buy |
| 2022-08-12 | Piper Sandler | Maintains | Overweight |
| 2022-07-19 | Lake Street | Maintains | Buy |
| 2022-05-20 | Lake Street | Initiate | Buy |
| 2021-08-13 | JMP Securities | Maintains | Market Outperform |
9 analysts have analysed APYX and the average price target is 4.08 USD. This implies a price increase of 34.65% is expected in the next year compared to the current price of 3.03.
The consensus rating for APYX MEDICAL CORP (APYX) is 77.7778 / 100 . This indicates that analysts generally have a positive outlook on the stock.